(24/7 MARKET NEWS) – Femasys Inc. (NASDAQ: FEMY) announced, after Tuesday’s market close, that it received 510(k) Clearance from the US Food and Drug Administration for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman’s fallopian tube, and followed up by reporting, yesterday, that it activated enrollment for its pivotal FemBloc trial at its first academic site located in Brooklyn, to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc.
Femasys is trading at $$1.66, up $0.14 (+9.21%), on 445.35K premarket shares traded.
Its 52-week range is $0.2479 to 1.79. It hit a new 52-week high yesterday and is well positioned to eclipse that today.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
